Uncategorized
No systemic complications observed with intravitreal sirolimus for noninfectious uveitis
DENVER — Intravitreal sirolimus does not seem to have any systemic adverse events in the treatment of noninfectious uveitis, according to a presentation here.In a poster presented at the Association for Research in Vision and Ophthalmology annual meeting, Daniel Rosberger, MD, and colleagues observed the whole-blood pharmacokinetics of intravitreal sirolimus in 14 patients who took part in the double-masked phase of the SAKURA Study 1.